TILARCO Canadian Trademark Information

On Monday, June 27, 2016, a canadian trademark registration was filed for TILARCO by PFIZER INC. *********, **********, ***** ****. The Canadian IP office has given the trademark application number of 1788644. The current status of this trademark filing is Interruption of proceeding. The correspondent listed for TILARCO is TORYS LLP of *********, **********, ***** **** The TILARCO trademark is filed in the description of Pharmaceutical preparations for the prevention and treatment of psychiatric diseases, degenerative nerve diseases and brain disorders, namely, mood, anxiety and cognitive disorders, Alzheimer's disease, cerebral palsy, Parkinson's disease, Huntington's disease and multiple sclerosis; Pharmaceutical preparations for the prevention and treatment of cranial and facial nerve disorders, connective tissue injuries, diseases and disorders, bone and cartilage injuries, diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neuromuscular and neurological diseases and disorders, namely, brain, central nervous system, muscle, ocular motility and spinal cord infections, injuries and diseases, and seizure disorders; Pharmaceutical preparations for the prevention and treatment of genitourinary diseases, namely, inflammatory pelvic diseases, urological and reproductive system diseases, disorders and infections, sexually transmitted diseases, erectile and sexual dysfunction, infertility and incontinence; Pharmaceutical preparations for the prevention and treatment of auto-immune, cardiovascular, gastrointestinal, hematologic, oncological, ophthalmological and respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of allergies, hypertension, menopause, diabetic neuropathy, arthritis, and pain; Antibiotics, anti-infectives, anti-inflammatories, anti-fungals, anti-virals, oral and injectable pharmaceutical contraceptives, human vaccines; Pharmaceutical preparations for the prevention and treatment of smoking habits and addictions; Pharmaceutical preparations for the prevention and treatment of renal disease and disorders; Pharmaceutical preparations for the prevention and treatment of diseases, disorders and infections of the endocrine system, namely growth and thyroid disorders; Pharmaceutical preparations for the prevention and treatment of muscular atrophy; Pharmaceutical preparations for the prevention and treatment of inflammatory diseases, namely inflammatory bowel diseases, inflammatory joint diseases, inflammatory connective tissue diseases, inflammatory muscle diseases and disorders; Pharmaceutical preparations for the prevention and treatment of metabolic diseases and disorders, namely diabetes, hypoglycemia, muscular dystrophy, sickle cell disease, and anemia. .